Monday, June 22

Browsing: V600EMutant

Survivors

EC Approves Encorafenib/Cetuximab/FOLFOX in 1L BRAF V600E–Mutant mCRC

By NewsCancerJune 22, 20260

The European Commission (EC) has approved encorafenib (Braftovi) in combination with cetuximab (Erbitux) and fluorouracil, leucovorin, and oxaliplatin (FOLFOX) for…

Support

Encorafenib/Cetuximab Plus FOLFIRI Improves PFS in BRAF V600E-Mutant mCRC

By NewsCancerFebruary 17, 20260

Encorafenib (Braftovi) in combination with cetuximab (Erbitux) and chemotherapy—fluorouracil, leucovorin, and irinotecan (FOLFIRI)—significantly improved progression-free survival (PFS) in patients with…

► Necessary Cookies Always Active

Necessary cookies enable essential site features like secure log-ins and consent preference adjustments. They do not store personal data.

► Functional Cookies Remark

Functional cookies support features like content sharing on social media, collecting feedback, and enabling third-party tools.

► Analytical Cookies Remark

Analytical cookies track visitor interactions, providing insights on metrics like visitor count, bounce rate, and traffic sources.

► Advertisement Cookies Remark

Advertisement cookies deliver personalized ads based on your previous visits and analyze the effectiveness of ad campaigns.

What's Hot

Longitudinal changes in DNA methylation in IDH-mutant glioma fuel disease progression through altered cell state differentiation

When to Consider Systemic Therapy for cSCC

EC Approves Encorafenib/Cetuximab/FOLFOX in 1L BRAF V600E–Mutant mCRC

Browsing: V600EMutant

EC Approves Encorafenib/Cetuximab/FOLFOX in 1L BRAF V600E–Mutant mCRC

Encorafenib/Cetuximab Plus FOLFIRI Improves PFS in BRAF V600E-Mutant mCRC

Longitudinal changes in DNA methylation in IDH-mutant glioma fuel disease progression through altered cell state differentiation

When to Consider Systemic Therapy for cSCC

EC Approves Encorafenib/Cetuximab/FOLFOX in 1L BRAF V600E–Mutant mCRC

The Moonlight Shift: Dr Joshua Richter on Myeloma, Myths, and the C-Word

Longitudinal changes in DNA methylation in IDH-mutant glioma fuel disease progression through altered cell state differentiation

When to Consider Systemic Therapy for cSCC

EC Approves Encorafenib/Cetuximab/FOLFOX in 1L BRAF V600E–Mutant mCRC

The Moonlight Shift: Dr Joshua Richter on Myeloma, Myths, and the C-Word

Latest Post

Longitudinal changes in DNA methylation in IDH-mutant glioma fuel disease progression through altered cell state differentiation

When to Consider Systemic Therapy for cSCC

EC Approves Encorafenib/Cetuximab/FOLFOX in 1L BRAF V600E–Mutant mCRC

Subscribe to Updates

What's Hot

Browsing: V600EMutant